Sign in

Oncology Brothers

@oncbrothers.bsky.social
815 followers 101 following 49 posts

Practice changing discussions by community oncologists: Drs. Rohit Gosain & Rahul Gosain. OwnViews/Not a Medical Advice. COI bit.ly/3o9agL3 Web: oncbrothers.com

PostsRepliesMedia
Reposted by Oncology Brothers
American Society of Clinical Oncology @ascocancer.bsky.social · 05/05/2025
Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25
0294
Reposted by Oncology Brothers
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 17/04/2025
Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy
ascopubs.org
Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches | JCO Oncology Advances
There have been significant advances in colorectal cancer (CRC) immunotherapy over the past decade, with incorporation into both the metastatic and adjuvant/neoadjuvant treatment spaces. However, ther...
262
Reposted by Oncology Brothers
Devika Das,MD MSHQS @devikadasmd.bsky.social · 21/04/2025
HER2 in NSCLC is underrecognized & complex. Grateful to join @cor2edmeded.bsky.social with an expert path colleague to discuss timely testing and clinical utility—now targetable on/off clinical trials. Thanks @oncbrothers.bsky.social for the invite! #lcsm #oncMedEd cor2ed.com/lung-connect...
cor2ed.com
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1 | COR2ED
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the
051
Oncology Brothers @oncbrothers.bsky.social · 10/04/2025
#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs with Dr. Aman Chauhan (full discussion and one page takeaway 👇👇) Full 🗣️: ⭐️ Oncbrothers.com/cabinet ⭐️ Also on the “Oncology Brothers” podcast #OncSky #MedSky #GiOnc
011
Reposted by Oncology Brothers
Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 08/04/2025
I recently had the privilege of joining the @oncbrothers.bsky.social to discuss all things #PancreaticCancer, including current and emerging treatment options that are bringing hope for better outcomes for patients. Many thanks👊 oncbrothers.com/pancreatic-a... www.cancernetwork.com/treatment-al...
021
Oncology Brothers @oncbrothers.bsky.social · 07/04/2025
Less than 2 months to #ASCO25! Join us to discuss the current SoC➕how the data from #ASCO25 will change/reinforce our practice! ⭐️ InPerson: May 31st, 2025 ⭐️ Location📍Marriott Marquis ⭐️ Time: 6:30-9:00PM ⭐️ Register bit.ly/aioasco25 #AdvInOnc25 #OncSky
031
Oncology Brothers @oncbrothers.bsky.social · 22/02/2025
#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara Full Discussion: ⭐️ Oncbrothers.com/zolbetuximab... ⭐️ Also on the “Oncology Brothers” podcast #gism #CanSky #OncSky
041
Oncology Brothers @oncbrothers.bsky.social · 18/02/2025
Treatment Algorithm series: discussion on HER2+ #BreastCancer ✅ APT data/TCHP ✅ Metastatic disease ✅ Her2/ER/PR+ Full discussion: ⭐️ oncbrothers.com/her2positive... ⭐️ www.cancernetwork.com/treatment-al... ⭐️ “Oncology Brothers” podcast #bcsm #CancerSky #OncSky @drsarahsammons.bsky.social
043
Reposted by Oncology Brothers
Roswell Park Comprehensive Cancer Center @roswellpark.bsky.social · 11/02/2025
What is Dr. Brian Betts most excited about for #TANDEM25? 🥁 Learn more about Roswell Park's involvement: www.roswellpark.org/newsroom/202...
032
Reposted by Oncology Brothers
Kari Wisinski, MD @kariwisinskimd.bsky.social · 12/02/2025
Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...
ascopubs.org
Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers
In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists. The statement...
144
Reposted by Oncology Brothers
Ravi Madan @ravimadan.bsky.social · 10/02/2025
As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer www.nature.com/articles/s41...
053
Oncology Brothers @oncbrothers.bsky.social · 11/02/2025
Treatment Algorithm series: starting off w/ TNBC discussion @vkaklamani.bsky.social ✅ Early disease ✅ ≥T2 or N+ disease ✅ Metastatic disease ✅ Low ER/PR+ Full 🗣️: ⭐️ oncbrothers.com/how-to-treat... ⭐️ www.cancernetwork.com/treatment-al... ⭐️ “Oncology Brothers” podcast #bcsm #BreastCancer
040
Reposted by Oncology Brothers
American Society of Clinical Oncology @ascocancer.bsky.social · 10/02/2025
The #GU25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation. Check out the latest practice-changing science in GU cancers here: brnw.ch/21wQBxm Co-sponsored by @astro-org.bsky.social and Society of Urologic Oncology
094
Oncology Brothers @oncbrothers.bsky.social · 06/02/2025
🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25: - Bladder Ca - Prostate Ca - RCC *Join us LIVE* 📅 Date: Feb 12, 2025 ⏰ Time: 6:00-8:00PM 📝 bit.ly/guaio25 #OncSky #MedSky #gusm #Oncology #Cancer #CanSky
071
Oncology Brothers @oncbrothers.bsky.social · 06/02/2025
AMPLIFY for 1L CLL now in @nejm.org 🔑 takeaways: 1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem) 2️⃣ AVO showed deeper responses but higher infection risk 3️⃣ New SoC for many #OncSky #CanSky #HemeSky
051
Reposted by Oncology Brothers
Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · 03/02/2025
Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social
13412
Reposted by Oncology Brothers
Freddy E Escorcia, MD/PhD @freddyeescorcia.bsky.social · 27/01/2025
Nice discussion on management of intermediate risk #HCC hosted by @oncbrothers.bsky.social! Cc: @markyarchoan.bsky.social #liversky #oncsky oncbrothers.com/liver-2024-4
oncbrothers.com
Intermediate HCC – the evolving role of Immunotherapy with Multimodality approaches
184
Reposted by Oncology Brothers
Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 28/01/2025
T-DXd approved today after progression on CDK4/6 inhibitor for HR+ HER2-low and HER2-ultralow metastatic breast cancer based on results of DESTINY-Breast06. #bcsm #oncsky
astrazeneca.com
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
0202
Reposted by Oncology Brothers
Sarah Sammons MD @drsarahsammons.bsky.social · 28/01/2025
T-Dxd approved as first line chemo in HR+, HER2 low or ultra low disease. Do all patients need it first line? Probably not. But great option for higher risk. #bcsm #oncosky
082
Reposted by Oncology Brothers
Krishan Jethwa @krishanjethwa.bsky.social · 25/01/2025
🔥🔥🔥BREAKWATER🔥🔥🔥 BRAF V600E mut #CRC SOC (FOLFOX) +/- encorafenib + cetuximab EC + FOLFOX shows: ✅⬆️ORR ✅Strong suggestion of ⬆️OS 🚨EC + FOLFOX is a new SOC‼️ Pub available: idp.nature.com/authorize?re... #GI25 @ascocancer.bsky.social
194
Oncology Brothers @oncbrothers.bsky.social · 25/01/2025
#GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Panc Ca 4. #StarterNET: GEP-NET 5. #CM8HW: dMMR/MSI-H mCRC 6. #BREAKWATER: BRAFV600E mCRC 7. ctDNA: #BESPOKE + SWOG80702 #OncSky #gism @ascocancer.bsky.social 1/8
2102
Reposted by Oncology Brothers
American Society of Clinical Oncology @ascocancer.bsky.social · 24/01/2025
Join us for Intersections: Personalized Risk Assessment for Gastrointestinal Cancers with Mary Uan-Sian Feng, MD. Gain insights on risk scores, biomarkers for screening, and more cutting-edge updates at #GI25!
1135
Reposted by Oncology Brothers
Dr Joseph McCollom DO @realbowtiedoc.bsky.social · 24/01/2025
So much excited data shared on Day 1️⃣ of #GI25 from #biomarker 🎯 testing in #esocsm #stcsm to the role of #RT in #esocsm in light 💡 of #ESOPEC. Excited for more great science and discovery on Day 2️⃣!
194
Oncology Brothers @oncbrothers.bsky.social · 17/01/2025
Datopotamab deruxtecan now #FDA approved off #TROPIONBreast01: #DatoDXd Vs Chemo post 1-2L HR+ mBC - ⏰ to 1st Rx: 8.2 vs 5mos (favoring Dato) - ⬆️ PFS 6.9mos vs 4.5 mos - Better AE + QoL favoring DatoDXd - AEs: Fatigue, infusion reactions, stomatitis #bcsm #OncSky #MedSky
072
Reposted by Oncology Brothers
Xiaojie (Zoe) Zhang @zoezhang.bsky.social · 15/01/2025
5/20 #TumorBoardTuesday 👩‍⚕️Mini Tutorial 2👩‍⚕️ Pt characteristics in INAVO120: No prior treatment for ABC PIK3CA mut a1c≤6.0, fasting BG<126 ~Half with ≥3 involved organ sites ~Half with liver involvement, ~40% with 🫁 involvement ~1/3 with 1° endocrine resistance, 2/3 with 2° @dr-rshatsky.bsky.social
264
Reposted by Oncology Brothers
Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · 13/01/2025
Who has tried to add Palbo to maintenance let + HP? Know it isn't "approved yet", but wasn't successful. Anyone been successful for coverage yet with #PATINA? @ptarantinomd.bsky.social @hoperugo.bsky.social @stolaney1.bsky.social @vkaklamani.bsky.social @jochien.bsky.social
4102
Reposted by Oncology Brothers
Dr. RShatsky @dr-rshatsky.bsky.social · 09/01/2025
Hello all, wanted to let you know about a fantastic interactive learning opportunity! This Tuesday the 14th my lovely fellow and I will be presenting Tumor board Tuesday #TBT about new developments in HR+ MBC! It will be 5pm pacific, 8pm eastern! #bcsm #OncSky #CanSky #MedSky #breastcancer #MBC
4429
Oncology Brothers @oncbrothers.bsky.social · 03/01/2025
#GISeries: #Zanidatamab was recently approved based off #HerizonBTC01! We 🗣️ design, findings, sequencing and AEs/management with Dr. Shubham Pant Full Discussion: - Oncbrothers.com/zanidatamab-... - Also on the “Oncology Brothers” podcast #OncSky #MedSky #gism #GI25
061
Reposted by Oncology Brothers
Yüksel Ürün @yukselurun.bsky.social · 02/01/2025
Adjuvant IO trials in muscle-invasive urothelial carcinoma: IMvigor010: Atezo DFS HR 0.89, OS HR 0.85. CheckMate 274: Nivo DFS HR 0.71, OS HR 0.76. AMBASSADOR: Pembro DFS HR 0.73, OS HR 0.98. #oncology #cancer @oncoalert.bsky.social @oncbrothers.bsky.social @erplimackmd.bsky.social @nejm.org
093
Reposted by Oncology Brothers
Yüksel Ürün @yukselurun.bsky.social · 02/01/2025
Early-onset colorectal cancer (<50 yrs) is rising, linked to factors like Western diets, obesity, and gut microbiota changes. Prevention & early detection strategies are vital. #ColorectalCancer #Oncology #CancerPrevention @oncoalert.bsky.social @oncbrothers.bsky.social rdcu.be/d49OZ
073
Reposted by Oncology Brothers
Amy C. Moore, PhD @acmoorephd.bsky.social · 28/12/2024
2024 was an exciting year for #lungcancer advances! As we mark the 20th anniversary of the discovery of EGFR's role in NSCLC, we celebrate this era of #precisionmedicine that is extending and improving patients' lives. #LCSM
0238
Oncology Brothers @oncbrothers.bsky.social · 28/12/2024
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA 1. #Tepotinib 2. #Osimertinib x2 3. #Alectinib 4. #Tarlatamab 5. #Zenocutuzumab 6. #Durvalumab x2 7. #Amivantamab x2 8. #Nivolumab (now SubQ) 9. #Ensartinib #lcsm #OncSky #MedSky #Cancer
12710
Oncology Brothers @oncbrothers.bsky.social · 24/12/2024
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA: 1. #Zanubrutinib 2. #Ponatinib 3. #LisoCel x2 4. #Imetelstat 5. #Epcortimab 6. #Daratumuab 7. #Axatilimab 8. #Isatuximab 9. #Asciminib 10. #ObiCel 11. #Revumenib #HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
0268
Reposted by Oncology Brothers
Vincent Rajkumar, MD @vincentrk.bsky.social · 08/12/2024
My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.
1336
Oncology Brothers @oncbrothers.bsky.social · 21/12/2024
#Encorafenib + #Ceruximab + mFOLFOX is approved in 1L for BRAFV600e based off #BREAKWATER - ORR 61% vs 40% - mDoR: 13.9mos vs 11.1mos - AEs:GI tox, rash #cansky #oncsky #gism
183
Reposted by Oncology Brothers
Yüksel Ürün @yukselurun.bsky.social · 20/12/2024
game-changer for tailoring treatment in high-risk cases. #Oncology #ProstateCancer @oncoalert.bsky.social @oncbrothers.bsky.social @apccc.bsky.social
0145
Oncology Brothers @oncbrothers.bsky.social · 20/12/2024
🚨In 5 weeks it’s #GI25🚨 Let’s discuss the current SoC and how the new data will change/reinforce our practice at #AdvInOnc25: - Upper GI - CRC - HepatoPanc & NET **Join us LIVE** 📅 **Date**: Jan 24, 2025 ⏰ **Time**: 6:00-8:00PM Register here: bit.ly/aiogi25 #OncSky #CanSky #MedSky #GISM
060
Reposted by Oncology Brothers
The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/12/2024
Just Out FDA 🇺🇸 approved ensartinib for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer ( #NSCLC ) 🫁who have not received prior ALK-targeted therapy. buff.ly/4gicU7q
063
Oncology Brothers @oncbrothers.bsky.social · 18/12/2024
Another ALK inhibitor (#ensartinib) gets FDA approval eXalt3 study: - 1L, Ph III, ALK+ mNSCLC vs Crizotinib - Ensartinib vs crizotinib (NR vs 12.7mos, HR: 0.45) - CNS ORR 64% w/ ensartinib vs 21% - AES: rash, 💪 pain, nausea #OncSky #MedSky #lcsm #CanSky
1113
Oncology Brothers @oncbrothers.bsky.social · 14/12/2024
#GISeries: #Hepatocellular Ca 2/4: 2nd Line Treatment and when to switch! 🌟IO, TKIs, #supponc in 2L 🌟AEs/Management Full 🗣️ - Oncbrothers.com/hcc-advanced... - cor2ed.com/hcc-connect/... - Also on “Oncology Brothers” podcast #OncSky #MedSky #gism @arndtvogel.bsky.social
010
Reposted by Oncology Brothers
Narjust Florez, MD, FASCO @narjustflorezmd.bsky.social · 14/12/2024
#HearHer in Brazil thanks to @paulobergerot.bsky.social and @crisbergerot.bsky.social Obrigada!
084
Oncology Brothers @oncbrothers.bsky.social · 12/12/2024
#SABCS24 Day 3 Highlights #CommunityOnc: 1. #EUROPA: ET vs XRT HR+ ≥70 yrs 2. #PATINA: CDK4/6 HR+ HER2+ new SoC 3. #COMET: DCIS 4. #SUPREMO: XRT post mastectomy 5. #INSEMA: ALNBx @sabcs.bsky.social @theaacr.bsky.social @drsarahsammons.bsky.social @erikahamilton9.bsky.social
172
Reposted by Oncology Brothers
Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · 11/12/2024
Great real world case discussion including #OSU @stoverlab.bsky.social @osuwexmed.bsky.social on the use of liquid biopsies in #mBC treatment decisions @sabcs.bsky.social #SABCS24 #bcsm Take Away - not ready for broad use in all pts, but may help in specific cases and holds promise for future
12210
Reposted by Oncology Brothers
Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/12/2024
The @oncbrothers.bsky.social are discussing the adjuvant CDK4/6 inhibitor landscape, Drs @laurahuppert.bsky.social and @neil-iyengarmd.bsky.social agree shared decision making with patients in key. #SABCS24
0155
Reposted by Oncology Brothers
Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · 12/12/2024
@aryaroy.bsky.social interviewing on behalf of @oncbrothers.bsky.social 🎙️ 🎬She did an amazing job!! 👏
092
Reposted by Oncology Brothers
Sarah Sammons MD @drsarahsammons.bsky.social · 12/12/2024
Wow! Median PFS was 44.3 months for pts treated with IBRANCE in combination with HP and endocrine therapy, and 29.1 months (95% CI: 23.3-38.6) for patients treated with HP and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94); p= 0.0074]. 44 month first-line PFS! @oncbrothers.bsky.social #SABCS
2226
Reposted by Oncology Brothers
Matthew Kurian, MD @matthewkurianmd.bsky.social · 12/12/2024
Fantastic event held yesterday by the @oncbrothers.bsky.social - truly thought provoking discussion with giants in the breast cancer space! Honored to be apart of it! @neil-iyengarmd.bsky.social @laurahuppert.bsky.so @drsgraff.bsky.social #sabcs2024 #signifymd
083
Reposted by Oncology Brothers
Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · 12/12/2024
@oncbrothers.bsky.social #AdvancesInOncology is about to start! Excited for a great session on recent treatment algorithms @drsgraff.bsky.social @neil-iyengarmd.bsky.social @laurahuppert.bsky.social @drsarahsammons.bsky.social
0135
Reposted by Oncology Brothers
Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · 12/12/2024
Wonderful discussion by @drsgraff.bsky.social and Dr Giuseppe Curigilano on treatment of #Her2 #breastcancer @oncbrothers.bsky.social #bcsm #sabcs
0133
Reposted by Oncology Brothers
Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/12/2024
Drs. @drsarahsammons.bsky.social and @drgattimays.bsky.social share pearls with @oncbrothers.bsky.social on managing early stage TNBC #SABCS24
0255